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Abstract
The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the
ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor
allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of
Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free
survival for combined and isolated CNS disease were 40.6% (25?1, 55?6) and 38.0% (26.2, 49.7) respectively. Univariate
analysis showed a significantly better survival for age,10 years, progenitor-B cell disease, good-risk cytogenetics and those
receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a
multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2?64, 95% CI 1?32, 5?31, p = 0?006
for OS). ALL R3 showed an improvement in outcome for CNS relapses treated with Mitoxantrone compared to Idarubicin; a
potential benefit for matched donor transplant for those with very early and early isolated-CNS relapses.
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Introduction
Acute lymphoblastic leukaemia (ALL) of childhood is a systemic
disease with a propensity for post-therapeutic recurrence in the
central nervous system (CNS) [1]. Modern chemotherapeutic
regimens have significantly decreased the incidence of all types of
relapses [2–9], primarily by intensification of systemic rather than
CNS directed therapy (cranial irradiation and intrathecal therapy)
[10,11]. Nevertheless, 20–40% of relapses continue to occur in the
CNS as either isolated (i-CNS) or combined (c-CNS) disease [10].
Management of these relapses remains problematic. In general,
early and combined relapses have a poorer prognosis when
compared with late and isolated CNS disease [12–15]. A
combination of 6–12 months systemic therapy with intrathecal
methotrexate, followed by cranial irradiation has yielded good
results [16–21]. Other approaches used have either focused on
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intensifying CNS directed therapy, such as craniospinal irradiation
[20], or intensifying systemic therapy with autologous [18] and
allogeneic stem cell transplantation (allo-SCT) [16,17,21].
As a significant proportion of patients relapsing off UK frontline
trials had CNS disease [10], we designed CNS directed therapy
into the ALL R3 relapse trial [22]. Drugs reported to cross the
blood brain barrier e.g. dexamethasone, high dose methotrexate
and high dose cytarabine were used in systemic chemotherapy
along with intrathecal methotrexate. At the end of three blocks of
chemotherapy, lasting 13 weeks, patients were either eligible for
cranial radiotherapy with continuing chemotherapy or allo-SCT
without cranial radiotherapy, based on risk stratification and
minimal residual disease (MRD) levels at the end of induction.
Patients with late isolated CNS relapses (more than 6 months after
stopping therapy) were not eligible for the allo-SCT option, based
on previous observations showing that the majority are cured with
chemotherapy and CNS directed radiotherapy [14,15]. All other
patients were treated on an uniform strategy for relapsed disease.
Very early CNS relapses (within 18 months from first diagnosis)
and early (more than 18 months from first diagnosis but within 6
months of stopping therapy) or late c-CNS relapses with high
MRD were eligible for allo-SCT. In patients with early or late c-
CNS disease where MRD results were not available, based on our
previous reported experience [14], allo-SCT was offered to all
those in whom relapse had occurred within 24 months of stopping
therapy. Relapses occurring 24 months after stopping therapy
were not eligible for an allo-SCT. Using these criteria, all early i-
CNS relapses were eligible for an allo-SCT. In ALL R3, a
randomisation of Mitoxantrone and Idarubicin was performed.
The Idarubicin metabolite idarubicinol is thought to cross the
blood brain barrier and Mitoxantrone to be active against
quiescent cells. Thus the former could be more active in CNS
disease and the latter in systemic relapses. We recently reported on
the premature closure of the randomisation due to overall benefits
of Mitoxantrone in all categories of relapsed ALL [22]. What
remained unclear, in the light of the different properties of the
drugs, whether this extended to those with CNS relapse? Though
the randomisation is now closed, the trial continues to recruit to
answer secondary objectives.
We now report on a prospective cohort analysis of the subgroup
of patients with CNS relapses treated on the ALL R3 trial. The
analysis thus includes patients recruited in both the randomised
and non-randomised phases of the trial.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supportive information; see Checklist S1 and
Protocol S1.
Patients
Patients aged 1–18 years with a first relapse of ALL, who had
not received an allo-SCT in first complete remission (CR1), were
eligible for the trial and were recruited from centres of the
Children’s Cancer and Leukaemia Group in UK and Ireland;
Australian and New Zealand Children’s Haematology and
Oncology Group and the Dutch Children’s Oncology Group.
This reports includes patients recruited between 1st January 2003
and 31st March 2011, with a median follow up of 46 months. The
trial was registered (ISRCTN 45724312 http://www.controlled-
trials.com/ISRCTN45724312/ALLR3) on 1st October 2003,
after recruitment started. At the time of trial start, it was
recommended that trials be registered but not necessarily prior
to subject recruitment, hence the short delay in ISRCTN
registration. The authors confirm that all ongoing and related
trials for this drug/intervention are registered.
Ethics Statement
Ethics approval obtained from Research Ethics Committee for
Wales in the UK, Research Ethics Committee, Our Lady’s
Children’s Hospital in Ireland, Committee for Human Research
(Arnhem – Nimegen Region) in the Netherlands and the Multi-
Region Ethics Committee in New Zealand. The following
Institutional Review Boards approved the study in Australia:
Ethics Committee, The Children’s Hospital at Westmead;
Children, Youth and Women’s Health Service Research Ethics
Committee, Government of South Australia; Ethics in Human
Research Committee, The Royal Children’s Hospital, Melbourne;
Royal Children’s Hospital and Health Service District Ethics
Committee, Queensland Government; Human Research Ethics
Committee C, Southern Health; Hunter New England Human
Research Ethics Committee, New South Wales Health; Mater
Health Services in Human Research Ethics Committee, Brisbane.
Written informed consent was obtained from patients or from
parents or legal guardians.
Definitions
i-CNS disease was defined as more than 5 or more white blood
cells per ml of CSF with morphological evidence of blasts or biopsy
proven recurrence in the eye or brain with no morphological bone
marrow involvement. A c-CNS relapse was defined as presence of
CNS disease with $5% blasts in a concomitant bone marrow
aspirate. An isolated bone marrow (i-BM) relapse was defined as
the presence of $25% blasts in the bone marrow. Patients were
defined as having achieved a second complete remission (CR2) if
they had ,5% blasts in the marrow; no blasts in the CSF or
regression of extramedullary disease including ocular infiltration at
the end of induction. Time to relapse was defined as, very early,
within 18 months from first diagnosis; early, after 18 months of
first diagnosis but within 6 months after end of therapy and late if
more than 6 months after end of therapy. Progression Free
Survival (PFS) was defined as time from registration date to the
first of induction failure ($5% blasts in the bone marrow or
persistence of CSF blasts at the end of induction), relapse, death
from any cause or a second malignancy. Overall Survival (OS) was
defined as time from registration to date of death from any cause.
For risk stratification at first diagnosis, the presence of ,25%
blasts in the marrow after 8 days (4-drug induction, NCI High
Risk) or 15 days (3-drug induction, NCI Standard Risk) were
defined as a rapid early response; $25% blasts in the same
categories was defined as a slow early response.
MRD
MRD was measured from marrow samples obtained at relapse
for those with c-CNS at the end of induction using clonotypic
markers for Ig/TCR rearrangements, by quantitative PCR as
previously described [22]. MRDlo was defined as fewer than 1024
cells with two sensitive markers (quantitative range 1024) and
MRDhi as at least one marker of 1024 cells or more at the end of
induction. End of induction MRD analysis was not possible in
patients with i-CNS [23].
Cytogenetics
Cytogenetic analysis was done in local laboratories and
reviewed centrally by the Leukaemia Research Cytogenetic Group
at the Northern Institute for Cancer Research, University of
Newcastle. Diagnostic and relapse karyotypes were used to classify
CNS Relapses in Childhood ALL
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patients with progenitor B-cell into good, intermediate and poor
risk cytogenetic subgroups based on the presence of specific
chromosomal abnormalities and characterised by their relapse risk
[24]. T-cell patients were characterised separately.
Treatment
The therapeutic protocol has been published [22] and available
at http://www.medicine.manchester.ac.uk/images/cancer/PAY
AC/documents/pdf/R3Protocolv4_31Aug2007.pdf. As per the
trial design, all very early relapses and early and late c-CNS
relapses with MRD levels $1024 (MRDhi) at the end of induction
were eligible for allo-SCT as were early i-CNS relapses where an
end of induction MRD assessment is uninformative. Where MRD
was unavailable for technical reasons in patients with early or late
c-CNS relapse, allo-SCT was recommended if disease recurrence
was within 24 months of stopping therapy. Early and late c-CNS
relapses with MRD ,1024 (MRDlo) and late isolated CNS
relapses were not eligible for transplantation, received 24 Gy as
fractionated cranial irradiation prior to week 14 and continued on
chemotherapy for a total of 104 weeks with no further intrathecal
methotrexate. Transplanted patients were conditioned with
cyclophosphamide and total body irradiation, There was a day 1
randomisation of Mitoxantrone versus Idarubicin. As previously
reported, this randomisation closed in December 2007 after 212
patients had been recruited and all subsequent patients registered
on the trial have received Mitoxantrone. Thus the patients
analysed represent those in the randomised cohort as well as those
enrolled post randomisation.
Statistical Analyses
This is a cohort analysis of those with CNS relapse from the
ALL R3 trial. PFS and OS, time was calculated in months and the
Table 1. Characteristics of those with isolated (i-CNS) or combined (c-CNS) CNS relapses compared with those with an isolated
bone marrow relapse (i-BM).
c-CNS i-CNS i-BM
N 43 80 207
Age at relapse in years
median (25th275th) 8?7 (6?8–13?7) 8?4 (6?1–11?5) 9?75 (7–13?4)
Range 2?5–18?8 2?0–17?9 1?1–18?8
Gender
Male:Female 27:16 61:19 104:103
Ratio 1?7:1 3?2:1 1:1
Time to Relapse in months
median (25th275th) 37 (23–47) 27 (21–34?3) 44 (33–61)
Range 6–92 5–90 5–155
Late 20 (47%) 12 (15%) 142 (69%)
Early 16 (37%) 55 (69%) 48 (23%)
Very Early 7 (16%) 13 (16%) 17 (8%)
Risk category (%)
Standard - 12 (15%) -
Intermediate 20 (47%) 68 (85%) 135 (65%)
High 23 (53%) - 72 (35%)
Immunophenotype
B:T 36:7 61:19 189:18
Ratio 5:1 3:1 11:1
CSF blast count
median (range) 97 (14–188) 97 (27–392) NA
Bone Marrow Blast %
median (range) 83?5 (48?5–95) NA 90 (78–95)
Cytogenetics (%)
progenitor B
Good 15 (35) 28 (35) 77 (37)
Intermediate 11 (25) 18 (23) 63 (30)
Poor 5 (12) 6 (8) 34 (16)
Unknown 5 (12) 9 (11) 15 (7)
T-cell 7 (16) 19 (24) 18 (9)
Relapses within 18 months of first diagnosis were termed as Very Early; after 18 months but within 6 months of stopping therapy as Early and after 6 months of
stopping therapy as Late. B = progenitor B cell; T = T-cell; CSF = cerebrospinal fluid. CSF blast count is presented as cells/ml of CSF. Risk stratification and cytogenetic
classification have previously been described.
doi:10.1371/journal.pone.0108107.t001
CNS Relapses in Childhood ALL
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Figure 1. Consort diagram. Showing the details of patients with central nervous system (CNS) relapse. c-CNS= combined bone marrow and CNS
relapse; i-CNS= isolated CNS relapse; TRM= treatment related mortality; SCT= allogenic bone marrow transplant; CRT= chemo-radiotherapy. *1
patient planned for SCT received CRT and vice-versa; #9 patients planned for SCT received CRT; +9 patients planned for SCT received CRT and 2
patients planned for CRT got SCT. No patients with i-CNS had detectable MRD in the marrow at the end of induction. Twenty four patients with c-CNS
has detectable marrow disease at week 5; 13 MRD positive and 9 MRD negative.
doi:10.1371/journal.pone.0108107.g001
Figure 2. Temporal pattern of relapses. Isolated (iCNS) and combined (c-CNS) relapses occur significantly earlier than those with isolated bone
marrow (iBM) relapses (Log rank p=,0.001). Figures in parenthesis show mean duration of remission in months for each group with 6 standard
deviation.
doi:10.1371/journal.pone.0108107.g002
CNS Relapses in Childhood ALL
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primary hypothesis generating analysis was performed using the
Kaplan Meier method and log rank test. Cox regression analysis
was done to assess the effect of type of CNS relapse after adjusting
for pre-specified prognostic covariates; age group (,10, $10
years), immunophenotype (B-cell, T-cell), time to relapse (very
early, early and late), cytogenetics (poor, intermediate, good,
failed/unknown and T-cell), treatment drug (Idarubicin, Mito-
xantrone) and sex. The Cox model for PFS was used to separately
assess interactions of the treatment drug with the following
variables; time to relapse, relapse site, immunophenotype and
actual SCT. Interactions with the type of CNS relapse were
assessed using the following covariates; time to relapse, immuno-
phenotype and CSF blast count (#50, 51–99, $100). For MRD at
day 35, only intermediate risk patients were included. The
proportional hazards assumption was assessed using Schoenfeld
Table 2. Differences in outcome in patients with CNS relapse, allocated either transplantation or chemoradiotherapy according to
whether they received Idarubicin or Mitoxantrone.
c-CNS i-CNS
n 43 80
Ida Mito Ida Mito
Induction
n 15 28 29 51
TRM 2 1 1 3
Failure 1 2 0 1
Withdrawn 0 1 0 1
Allocated Treatment*
n 12 24 28 46
SCT 9 21 25 36
No SCT 3 3 3 10
Post Induction
n 12 24 28 46
TRM 0 0 2 2
Relapse 1 3 2 1
Withdrawn 0 2 0 2
SCT Time point
Not Reached 0 0 0 3
Reached 11 19 24 38
Outcome
SCT Group 8 16 21 30
Actual SCT 8 15 13 21
CR2 3 12 5 16
TRM 3 1 1 2
Relapse 2 2 6 3
Accidental Death 0 0 1 0
No-SCT 0 1 8 9
CR2 0 0 0 4
TRM 0 1 0 0
Relapse 0 0 8 5
Non-SCT Group 3 3 3 8
Actual non-SCT 3 2 3 6
CR2 1 1 3 5
TRM 1 0 0 0
Relapse 1 1 0 1
SCT 0 1 0 2
CR2 0 1 0 1
Second Malignancy 0 0 0 1
c-CNS = combined CNS relapse; i-CNS = isolated CNS relapse; TRM=Therapy related mortality; SCT = allogeneic transplantation; CR2 = second remission; Ida = Idarubicin;
Mito =Mitoxantrone. *Patients allocated SCT were, all those with very early relapse; early i-CNS relapses and early and late c-CNS relapses with MRD $1024 at the end of
induction. Where MRD was not evaluable, decision to transplant was based on duration of CR1. All other patients were allocated chemoradiotherapy.
doi:10.1371/journal.pone.0108107.t002
CNS Relapses in Childhood ALL
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residuals and was found to be acceptable in all cases. This analysis
was performed using STATA version 11.
The cumulative distribution function was used to describe
potential differences between age groups by treatment related
events, defined as post induction failure and toxic-related deaths.
For censored patients, time from registration to date last known
alive or date of death if the patient did not have a disease related
event was used. For toxic deaths, time to event was defined as time
from date of registration to date of death if cause of death was due
to toxicity.
Results
Three hundred and thirty children were recruited to the trial
between January 1, 2003 and March 31, 2011. Of these, 207 had
i-BM; 43 c-CNS and 80 i-CNS relapses (Table 1 and Figure 1).
Comparing the two groups, CNS recurrence, in particular i-CNS
was significantly higher for males (p =,0?001). Of the 44 T-cell
relapses, 26 (59%) had recurrence in the CNS compared to 97
(34%) of 286 progenitor B-cell relapses (p = 0?001). The temporal
patterns of CNS relapses were similar and peaked before i-BM
disease (p =,0.001) (Figure 2). The median follow up was 46?1
(39?8–52?7) months for all patients (95% CI, reverse Kaplan-
Meier method). The estimated 3-year PFS and OS of the whole
group (n= 330) were 51?2% (45?3, 56?9) and 58?3% (52?3, 63?9)
respectively. Further analyses with respect to this report are
restricted to the outcome of those with a CNS relapse (n = 123).
The estimated 3-year PFS for those with c-CNS and i-CNS were
40?6% (25?1, 55?6) and 38?0% (26?2, 49?7) p = 0.876 respectively.
The estimated 3-year OS for those with c-CNS and i-CNS were
40?9% (24?9, 56?3), 50?8% (37?5, 62?6) p = 0?303 respectively.
A schema of the risk stratified treatment approach, based on
duration of first remission, immunophenotype and site of relapse,
for those with CNS disease is shown in Table S1 in File S1, along
with the numbers of patients in each risk group and the allocation
for allo-SCT or chemoradiotherapy. Table 2 shows the progres-
sion with therapy. 30/43 (70%) and 62/77 (81%) evaluable c-CNS
and i-CNS patients completed 3 blocks of intensive therapy to
reach the time to transplant (chi-squared test, p = 0.182).
Excluding the 13 patients who were withdrawn or had an event
during induction, as per the stratification adopted in the trial, 91
patients were eligible for allo-SCT and 19 for chemoradiotherapy.
We have previously reported a better outcome for 87 of the 123
patients with CNS relapse who received Mitoxantrone [22]. This
continues to the case in this extended cohort with a significant (log
rank p= 0.042) increase in disease recurrence in patients who
received Idarubicin (Figure S1 in File S1). Mitoxantrone was
associated with a significant PFS and OS 3-year survival rates
advantage in patients eligible for/or who received an allo-SCT
when compared to those patients eligible for/who received
Idarubicin (Table 3 and Figure S2 in File S1).
Fifty one i-CNS patients, with very early or early relapse and
eligible for allo-SCT reached the time point for transplantation
(week 13). In the Idarubicin group, 3 of 4 very early and 10 of 17
early relapses were transplanted. In the Mitoxantrone group, all 5
very early and 16 of 25 early relapses were transplanted. The 3-
year PFS and OS for 21 i-CNS patients treated with Idarubicin
was 21.2 [11.9, 30.5] and 35.6 [24.9, 46.3]; and for 30 patients
treated with Mitoxantrone were 60.7 [50.8, 70.6] and 70.8 [61.4,
80.2] respectively (p = 0.027 for PFS and p= 0.032 for OS). Of
those eligible for but not transplanted, 13/17 have relapsed. In
contrast, there has been only 1 relapse in the 11 patients with late
i-CNS relapses not eligible for allo-SCT. For those with c-CNS
relapses, the numbers are small, but 15 of 24 patients eligible for
allo-SCT are in CR2 (3-year PFS 62.2 [51.4, 73], 3-year OS 65.5
[54.6, 76.4]).
Table 4 shows the 3-year PFS, OS and the univariate
unadjusted hazard ratio (HR) for PFS and OS for various factors
contributing to outcome. From the analysed risk factors at original
diagnosis, presenting age, but not white cell count or early
response to therapy were predictive of outcome at CNS relapse. At
relapse, late recurrence, age less than 10 years, progenitor B-cell
disease, standard and intermediate risk groups, good risk
cytogenetics and those who received Mitoxantrone had a better
prognosis. As the randomisation was terminated early there was an
imbalance in patients receiving Mitoxantrone. Adjusting for the
variables (age at relapse, time to relapse, cytogenetics, treatment
drug and gender) in a multivariate analysis, showed a poorer
outcome for those with c-CNS relapse (HR 1?82, 95% CI 0?98,
3?40, p = 0?059 c-index= 0.70 95% CI 0.64,0.75 for PFS and HR
2?64, 95% CI 1?32, 5?31, p = 0?006 c-index= 0.72 95% CI
0.66,0.78 for OS).
Table 3. Endpoint of PFS and OS in patients with CNS relapse grouped by treatment allocation, and according to drug received
Idarubicin vs Mitoxantrone.
n 3 yr PFS (95% CI) p-value 3 yr OS (95% CI) p-value
Intended SCT 91
Idarubicin 34 22?2% (9?9, 37?4) 34?0 (18?7, 49?9)
Mitoxantrone 57 55?0% (39?4, 68?1) 0?02 63?0% (46?7, 75?5) 0?02
Intended No SCT 19
Idarubicin 6 66?7% (19?5, 90?4) 66?7% (19?5, 90?4)
Mitoxantrone 13 61?5% (26?6, 83?7) 0?90 68?6% (21?3, 91?2) 0?81
Actual SCT 60
Idarubicin 21 36?4% (16?6, 56?6) 35?7% (16?1, 56?0)
Mitoxantrone 39 72?2% (52?8, 84?7) 0?02 76?0% (55?6, 87?9) 0?01
Actual No SCT 32
Idarubicin 14 28?6% (8?8, 52?4) 50?0% (22?9, 72?2)
Mitoxantrone 18 50?4% (22?6, 72?9) 0?20 59?2% (17?6, 85?4) 0?39
doi:10.1371/journal.pone.0108107.t003
CNS Relapses in Childhood ALL
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The late isolated relapses in the i-CNS group have the best
outcome (10 of 11 patients are in CR2) and a better salvage rate,
so a difference in the adjusted outcome is to be expected.
Additionally for PFS multivariate analyses separate assessments of
interaction of the treatment drug with time to relapse, relapse site,
immunophenotype and actual SCT were not statistically signifi-
cant. Similarly, the interaction of type of CNS with time to relapse,
immunophenotype and CSF blast count were not statistically
significant. Exploratory multivariate analysis using pre-specified
subgroups showed that age at relapse $10 years had an
unfavourable outcome (HR 1.91, 95% CI 1.11, 3.28, p= 0.018
for PFS and HR 1.90, 95% CI 1.07, 3.35, p = 0.027 for OS). We
tested the effect of potential imbalances of prognostic factors in the
two age groups. There were proportionately more c-CNS, males,
standard risk, T-cell immunophenotype and fewer good risk
cytogenetic patients in the $10 year age group (Table 5).
Figure 3, shows the risk ratios for PFS, for age at relapse
according to the different characteristics. Patients age $10 years
had a significantly worse outcome in all categories except in those
who had good risk cytogenetics. To investigate whether differences
seen between the two age groups was due to disease progression
and/or side effects of treatment we examined the cumulative
percentage of events. As shown in Figure 4 although disease
related events are similar between the two groups 24/77 (31%)
and 13/44 (30%) for age groups ,10 and .=10 respectively
(p = 0.852), older patients relapsed earlier. Overall treatment
related mortality was higher in older patients in all phases of
therapy 10/77 (13%) and 13/44 (30%) for age groups ,10 and .
=10 respectively (p = 0.026).
Of the 36 second relapses, five (14%) (Four with i-CNS and one
with c-CNS) have subsequently achieved CR3 (Table S2 in File
S1). Of the 28 patients who relapsed after either receiving a
transplant or cranial radiotherapy, there were 19 CNS (17 i-CNS
and 2 c-CNS) and 9 i-BM relapses. Thirteen of the 19 CNS
relapses were patients who had not been transplanted but had
received cranial irradiation. Six of the nine post transplant relapses
in the i-CNS group occurred in those with a very early relapse.
Thus, salvage after a CNS relapse remains low with a high
frequency of disease recurrence in those who received cranial
irradiation.
Discussion
The survival rates of patients treated with mitoxantrone
reported here are better than we have previously reported for c-
CNS and comparable for those with i-CNS [14]. All relapses
described here are of children treated on protocols in existence
from 2000 onwards. In the UK these are primarily ALL97 [25]
and ALL2003 [26]. This analysis suggests that there has been a
change in pattern of CNS relapses in the post 2000 era. While we
previously reported i-CNS to c-CNS ratio of 1?1[10], in this report
it is 1?9. There also appears to be a temporal change in the pattern
of i-CNS relapses with a decrease in very early from 42% to 16%
and a proportionate increase in early to 69% from 45%. Thus with
Table 5. Characteristics of patients aged younger than 10, or 10 and older with CNS relapses.
Age at Relapse (years) ,10 $10
n 78 45
CNS relapse (%)
Isolated 53 (68) 27 (60)
Combined 25 (32) 18 (40)
Gender
Male: Female 51:27 37:8
Time to Relapse (%)
median in months (range) 29 (5–92) 33 (6–90)
Late 18 (23) 14 (31)
Early 48 (62) 23 (51)
Very Early 12 (15) 8 (18)
Risk category
Standard 4 (5) 8 (18)
Intermediate 63 (81) 25 (55)
High 11 (14) 12 (27)
Immunophenotype
B:T 66:12 31:14
Cytogenetics (%)
progenitor-B cell
Good 32 (41) 11 (24)
Intermediate 18 (23) 11 (24)
Poor 5 (6) 6 (13)
Unknown 11 (14) 3 (7)
T-cell 12 (15) 14 (22)
doi:10.1371/journal.pone.0108107.t005
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time there is an apparent shift towards earlier and c-CNS relapses
both of which are associated with an inferior outcome.
The rarity of relapse makes subgroup analyses problematical.
However relapsed ALL remains the leading cause of death in
children with cancer and our observations may help physicians
managing such patients. The key findings of this study are the
benefits of, Mitoxantrone for all patients and allo-SCT for early
and very early i-CNS relapses. We have previously suggested that
the benefit of Mitoxantrone may be related to its toxic effect on the
microenvironment [22]. Allogeneic transplantation may have a
similar effect, though this study is not designed to answer this
question. What is evidenced is that after intensive systemic
therapy, consolidation of remission with allo-SCT offers a better
curative approach over targeted CNS directed therapy for very
early and early CNS relapses. In those with early and very early i-
CNS disease, 71% of those allocated allo-SCT but not
transplanted (receiving chemoradiotherapy) suffered a second
relapse, while recurrence rates were 21% in those transplanted.
Late i-CNS relapses occurring off modern intensive chemotherapy
regimens continue to be curable with chemo-radiotherapy. There
were only a few patients with c-CNS disease not eligible for
transplantation. Of the 5 not transplanted, 2 are in CR2. Of the 23
transplanted, 15 are in CR2. Given the poor salvage rate after a
second relapse, a more simple approach would be to offer an allo-
SCT to all CNS relapses except those with a late i-CNS
recurrence.
The poorer outcome of adolescent patients with CNS relapse
has been previously reported in a retrospective analysis. Therapy
was not uniform and other potential contributing factors to the
worse outcome were not examined [9]. In our study, a uniform
therapeutic approach, stratified for risk, was taken for all patients,
with good results in those aged under 10 but not for older children.
The older age group had proportionately more patients with T-
cell disease and less with good-risk cytogenetics. The inferior
Figure 3. Age at relapse (,10 or $10 years) effect on progression-free survival by patient characteristics, from Cox models with
interactions. White cell count is the presenting count (6109/L) at first diagnosis. Relative risk ratios indicate that all subgroups show a poorer
outcome in those $10 years, except good risk cytogenetics.
doi:10.1371/journal.pone.0108107.g003
CNS Relapses in Childhood ALL
PLOS ONE | www.plosone.org 10 October 2014 | Volume 9 | Issue 10 | e108107
survival of very early and T-cell relapses has been a consistent
theme [13–15] and in this study, T-cell relapses occurred earlier
and in older patients. Good-risk cytogenetics are associated with
late relapses [24] and a better prognosis in older patients [27].
Thus both immunophenotype and cytogenetics contributed to the
earlier relapse pattern observed in those $10 years of age.
The worse outcomes for the $10 year age group in this trial
were primarily related to toxicity. Paediatric type protocols have
considerably improved the outcome of adolescents and young
adults newly diagnosed with ALL [28,29]. This improvement
comes at a price of increased toxicity, primarily that of sepsis,
osteonecrosis and thrombosis [29,30]. In ALL R3 we shortened
the duration of steroid exposure and used a pegylated derivative to
decrease the dose of asparaginase. Neither thrombosis nor
osteonecrosis have been of significance though sepsis in older
children remains a problem. As older patients tend to relapse early
further cytotoxic intensification is not possible. The successor trial
for ALLR3, IntReALL 2010 [31] will use the non-toxic targeted
drug Epratuzamab in conjunction with post induction therapy
patients with late and early CNS relapses. Though Epratuzamab
does not cross the blood-brain, our data suggests that systemic
therapy is key to maintaining remission in those with a CNS
relapse. Thus IntReALL will evaluate if a non-toxic intervention is
able to improve the outcome of older patients with relapses in the
CNS.
The pathogenesis of CNS disease in ALL remains enigmatic,
hindering the development of more targeted less toxic strategies.
Recent evidence suggests that leukemic blasts circulate in the
blood to the CNS, where they transgress blood-brain and blood-
CSF barriers by diapedesis rather than by haemorrhage [32]. The
subarachnoid tissue may then provide a chemoprotective micro-
environment for lymphoblasts [33] giving rise to recurrence once
therapy is discontinued. This supports the use of systemic therapy
to prevent and treat CNS recurrence. As illustrated by this report,
Figure 4. Cumulative percentage of events, in those aged,10 and$10 years at first relapse. (A) Therapeutic failure, which includes both
induction failures and second relapses. (B) Treatment related deaths.
doi:10.1371/journal.pone.0108107.g004
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while the management of relapsed CNS disease using intensive
systemic approaches has met with some success, it remains less
than satisfactory. We need new agents and novel approaches,
based on a better understanding of the disease process. A good
proportion of patients eligible for early phase trials are in the older
age group. Thus when evaluating new agents, we will also need to
allow for age related variations in the therapeutic response, both
with regards to efficacy and toxicity, lest we come to inexact
conclusions.
Supporting Information
File S1 Additional information on survival and further
relapse rates by drug (Idarubicin & Mitoxantrone).
Details of risk stratification and treatment allocation and also
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